<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310583</url>
  </required_header>
  <id_info>
    <org_study_id>2005-000411-10</org_study_id>
    <secondary_id>BfArM61-3910-4030984</secondary_id>
    <secondary_id>4478944789</secondary_id>
    <secondary_id>EV2005-2509</secondary_id>
    <nct_id>NCT00310583</nct_id>
  </id_info>
  <brief_title>Effects of Pregabalin on Mechanical Hyperalgesia</brief_title>
  <official_title>Effects of Pregabalin on Mechanical Hyperalgesia - EPOM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professional Associations Clinic Bergmannsheil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Professional Associations Clinic Bergmannsheil</source>
  <brief_summary>
    <textblock>
      The aim of this randomized placebo-controlled study is to evaluate the effects of analgetics
      for neuropathic pain on mechanical hyperalgesia as a kind of evoked pain. Therefore the
      number of responders and non-responders on pregabalin will be evaluated in respect of
      mechanical hyperalgesia (stimulus-response-function (SRF) on static punctual stimuli evoking
      pain determined via pinprick). The hypothesis is that in the placebo group the amount of
      non-responders is increased.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial is intended to be the first in a series of trials that will
      assess the efficacy of drugs, which relieve neuropathic pain, on stimulus-evoked pain (here:
      mechanical hyperalgesia to static punctate stimuli). Most drugs in this class (e.g.
      Gabapentin or NMDA receptor inhibitors) have NNT beyond 3 in patients with chronic pain, due
      to a response rate of 30 to 50 %. One potential reason for this low overall efficacy might be
      the presence of different pathophysiological mechanisms in subgroups of patients, who suffer
      from the same disease (e.g. postherpetic neuralgia, diabetic neuropathy). These mechanisms
      may include central sensitization on one hand and peripheral degeneration of afferent fibers
      on the other hand.

      In this trial, we will use a battery of mechanical and thermal Quantitative Sensory Tests
      (QST), using non-nociceptive and low-intensity painful stimuli, to identify a subgroup of
      patients with mechanical hyperalgesia. To overcome the well-known low response rate in trials
      with neuropathic pain patients, an enriched design comparing active drugs with placebo will
      be performed, including only patients with high intensity of on-going pain in combination
      with mechanical hyperalgesia as sequelae of different, but well defined neurological
      disorders. The blinded phase of the trial will be restricted to so-called responders, i.e.
      patients with a clinically meaningful pain reduction of at least 30% in the primary end point
      (mechanical hyperalgesia). The second objective of this trial is to evaluate, whether the
      anti-hyperalgesic effect of the active drug is dependent on the QST profile.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of responders and non-responders in respect of mechanical hyperalgesia (stimulus-response-function (SRF) on static punctual stimuli evoking pain determined via pinprick)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of mechanical hyperalgesia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pain (numerical rating scale)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Symptom Inventory score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable CDT = cold detection threshold,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable HDT = heat detection threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable TSL = thermal sensory limen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable PHS = number of paradoxical heat sensations during the TSL Procedure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable CPT = cold pain threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable HPT = heat pain threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable MDT = mechanical detection threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable MPT = mechanical pain threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable ALL = dynamic mechanical allodynia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable WUR = windup ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable VDT = vibration detection threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable PPT = pressure pain threshold)</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Tactile Hyperalgesia</condition>
  <condition>Neuropathic Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Recruitment:

          -  Age above 18 years;

          -  Neuropathic pain of at least 4/10 for at least 6 months;

          -  Mechanical hyperalgesia;

          -  One of the following diagnoses: peripheral nerve lesion, plexus lesion, radicular
             lesion, spinal lesion, polyneuropathy, postzosteric neuralgia;

          -  No nerve block or other interventional treatment for at least 4 weeks;

          -  Constant medication for at least 4 weeks;

          -  Signed informed consent;

          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
             or equivalent units of HCG) within 72 hours prior to the start of study medication;

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 4 weeks after the
             study in such a manner that the risk of pregnancy is minimized.

        Enrolment open titration:

          -  All principal inclusion criteria at recruitment

          -  Relevant mechanical hyperalgesia: SRF affected/control at least 2.0 with a minimal SRF
             of 0.8.

        Enrolment double-blind phase:

          -  At least 30% reduction in mechanical hyperalgesia (SRF) in the open titration;

          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
             or equivalent units of HCG) within 72 hours prior to the start of study medication;

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 4 weeks after the
             study (see above recruitment).

        Exclusion Criteria:

          -  Anaphylaxis on the active component or any other component of Lyrica or the placebo
             (LyricaÂ®: pregabalin, lactose-monohydrate, corn starch, talcum; capsule shells:
             gelatine, titanium dioxide (E 171), natriumdodecylsulfat, high dispersive
             siliciumdioxide, purified water; ink: shellac, black iron(II,III)-oxide (E 172),
             propyleneglycol, kaliumhydroxide; additionally in placebo: microcrystalline cellulose,
             sucrose octaacetate, magnesium stearate)

          -  Intake of gabapentin or pregabalin within the last 4 weeks prior to recruitment

          -  Any surgery within the last two months or any scheduled surgery within the study
             period (20 weeks);

          -  Concurrent unstable disease involving any system, e.g. advanced carcinoma, acute
             myocardial infarction, renal failure, or any other condition that in the opinion of
             the Investigator would deem the patient unsuitable for the study;

          -  History of cerebral vascular or other cerebral disease;

          -  Concurrent chronic or acute pain of other origin (osteoarthritis), which is not
             treated effectively

          -  Concurrent severe mental deficit, e.g. psychiatric disorders as defined by DSM IV
             including schizophrenia, mood disorders, organic brain syndrome, psychotic/delusional
             disorders, serious psychosis;

          -  Concurrent serious neurological disease, e.g. dementia, multiple sclerosis, or any
             other disease that would have impact on the ability of the patient to give their
             consent for the participation in the study or influences the pain perception;

          -  Concurrent atrioventricular block second degree or higher

          -  Concurrent renal failure (CLcr &lt; 30 ml/min)

          -  Concurrent hereditary galactose-intolerance

          -  Concurrent lapp-lactase insufficiency

          -  Concurrent glucose-galactose-malabsorption

          -  Concurrent sub-optimal stabilized Diabetes Mellitus (Hb1Ac &gt; 12%)

          -  Clinical apparent overdosage of opioids or psychopharmaca

          -  Recent history (6 months) or current evidence of alcohol or drug abuse;

          -  Participation in any other investigational drug or therapy study within the previous
             90 days;

          -  Women who are pregnant or breastfeeding;

          -  Women with a positive pregnancy test on enrollment or prior to study drug
             administration;

          -  Women of childbearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period and for up to 4 weeks after the
             study. Women practicing abstinence should use a reliable method of contraception
             (except birth control pills) if they choose to become sexually active during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Maier, Prof. MD.</last_name>
    <role>Study Director</role>
    <affiliation>Professional Associations Clinic Bergmannsheil , Dept. of Pain Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Maier, Prof. MD</last_name>
    <phone>+49 (0)234 - 302 - 6366</phone>
    <email>christoph.maier@rub.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Kliniken Bergmannsheil, Dept. of Anaesthesiology, Intensive Care and Pain Therapy, Dept. of Pain Therapy</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christhop Maier, Prof. MD</last_name>
      <phone>+49(0)234-302-6366</phone>
      <email>christoph.maier@rub.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Maier, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Scherens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Therapy, Dept. of Anaesthesiology and Intensive Care Medicine, University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Petzke, MD</last_name>
      <phone>+49(0)221-478-3627</phone>
      <email>frank.petzke@uni-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Thorsten Giesecke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Petzke, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Duesseldorf, Dept. of Paintherapy, Dept. of Anaesthesiology</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rainer Freynhagen, MD</last_name>
      <phone>+49(0)211-81-19157</phone>
      <email>freynhagen@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Rainer Freynhagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Schmitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Busche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesiology, University Hospital of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Koppert, PD MD</last_name>
      <phone>+49(0)9131-85-32901</phone>
      <email>koppert@kfa.imed.uni-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Koppert, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitute of Physiology and Experimental Pathophysiology</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian MaihÃ¶fner, MD</last_name>
      <phone>+49(0)9131-85-22498</phone>
      <email>christian.maihoefner@neuro.imed.uni-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Christian MaihÃ¶fner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological University Hospital, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingolf C BÃ¶tefÃ¼r, MD</last_name>
      <phone>+49(0)761-270-5001</phone>
      <email>botefur@nz.ukl.uni-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Ingolf C BÃ¶tefÃ¼r, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neuroradiology, Neurological Health Care Center, University Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Stippich, PD MD</last_name>
      <phone>+49(0)6221-56-39607</phone>
      <email>christoph.stippich@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Stippich, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Neurological Section, Pain Research and Therapy, UniversitÃ¤tsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Baron, Prof. MD</last_name>
      <phone>+49(0)431-597-1809</phone>
      <email>r.baron@neurologie.uni-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Baron, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Binder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janne Ludwig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J Schattschneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Care Centre, Dept. of Neurology, Johannes Gutenberg University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Birklein, Prof. MD</last_name>
      <phone>+49(0)6131-17-3270</phone>
      <email>birklein@neurologie.klinik.uni-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Frank Birklein, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Gerber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roman Rolke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DRK - Pain Centre Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susann Seddigh, MD</last_name>
      <phone>+49(0)6131-988510</phone>
      <email>susann.seddigh@drk-schmerz-zentrum.de</email>
    </contact>
    <investigator>
      <last_name>Susann Seddigh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Therapy, Dept. of Anaestesiology and Intensive Care Medicine, Clinical Medicine Mannheim, University of Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike Friess, MD</last_name>
      <phone>+49(0)621-383-2608</phone>
      <email>ulrike.friess@anaes.ma.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Friess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anesthesiology and Surgical Intensive Care Medicine, University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther Pogatzki-Zahn, PD MD</last_name>
      <phone>+49(0)251-834-7258</phone>
      <email>pogatzki@anit.uni-muenste.de</email>
    </contact>
    <investigator>
      <last_name>Esther Pogatzki-Zahn, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interdisciplinary Dept. of Pain Management, Dept. of Anaesthesiology, Ludwig-Maximilians-University</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanhnaz C Azad, PD MD</last_name>
      <phone>+49(0)89-7094-4464</phone>
      <email>Shahnaz.Azad@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Shanhaz C Azad, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meike Lauchert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Huge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Universtity Hospital TU Munich</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas R Toelle, Prof. MD</last_name>
      <phone>+49(0)89-4140-4603</phone>
      <email>toelle@neuro.med.tu-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas R Toelle, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Valet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Till Sprenger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorothee Nietzsche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Bach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Achim Berthele, PD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Transfusion Medicine, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Bredanger, MD</last_name>
      <phone>+49(0)7071-29-85612</phone>
      <email>sabine.bredanger@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Sabine Bredanger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klaus Unertl, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard G. Landwehrmeyer, Prof. MD</last_name>
      <phone>+49(0)731-500-50950</phone>
      <email>bernhard.landwehrmeyer@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Bernhard G. Landwehrmeyer, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland Klug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Hospital, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Sommer, Prof. MD</last_name>
      <phone>+49(0)931-201-23763</phone>
      <email>sommer@mail.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Sommer, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurcan Uceler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neuropathischer-schmerz.de/</url>
    <description>German Network Neuropathic Pain</description>
  </link>
  <link>
    <url>http://www.bmbf.de/</url>
    <description>German Ministry of Education and Research</description>
  </link>
  <link>
    <url>http://www.bfarm.de</url>
    <description>German Federal Institute for Drugs and Medical Devices</description>
  </link>
  <link>
    <url>http://www.ruhr-uni-bochum.de/ethik/</url>
    <description>Ethics Committee, Medical Department of the Ruhr-University Bochum</description>
  </link>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>April 4, 2007</last_update_submitted>
  <last_update_submitted_qc>April 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2007</last_update_posted>
  <keyword>tactile hyperalgesia</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>enriched design</keyword>
  <keyword>peripheral nerve lesion</keyword>
  <keyword>plexus lesion</keyword>
  <keyword>radicular lesion</keyword>
  <keyword>spinal lesion</keyword>
  <keyword>polyneuropathy</keyword>
  <keyword>postzosteric neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

